IL33 activates CD8+T and NK cells through MyD88 pathway to suppress the lung cancer cell growth in mice
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
IL33 activates CD8+T and NK cells through MyD88 pathway to suppress the lung cancer cell growth in mice
Authors
Keywords
-
Journal
BIOTECHNOLOGY LETTERS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-03-05
DOI
10.1007/s10529-020-02815-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils
- (2017) Valeria Lucarini et al. OncoImmunology
- Exogenous IL-33 Restores Dendritic Cell Activation and Maturation in Established Cancer
- (2016) Donye Dominguez et al. JOURNAL OF IMMUNOLOGY
- Emerging drugs for squamous cell lung cancer
- (2015) Haiying Cheng et al. EXPERT OPINION ON EMERGING DRUGS
- Dendritic-cell vaccines on the move
- (2015) Rachel Lubong Sabado et al. NATURE
- Releasing the Brakes on Cancer Immunotherapy
- (2015) Antoni Ribas NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- T-bet– and STAT4–dependent IL-33 receptor expression directly promotes antiviral Th1 cell responses
- (2015) Claudia Baumann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- IL-33/ST2 pathway contributes to metastasis of human colorectal cancer
- (2014) Xuejian Liu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Dynamics of the IL-33/ST2 network in the progression of human colorectal adenoma to sporadic colorectal cancer
- (2014) Guanglin Cui et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Biliary repair and carcinogenesis are mediated by IL-33–dependent cholangiocyte proliferation
- (2014) Jun Li et al. JOURNAL OF CLINICAL INVESTIGATION
- Tumoral Expression of IL-33 Inhibits Tumor Growth and Modifies the Tumor Microenvironment through CD8+T and NK Cells
- (2014) Xin Gao et al. JOURNAL OF IMMUNOLOGY
- High Serum Levels of the Interleukin-33 Receptor Soluble ST2 as a Negative Prognostic Factor in Hepatocellular Carcinoma
- (2014) Dominik Bergis et al. Translational Oncology
- Transgenic expression of IL-33 activates CD8+ T cells and NK cells and inhibits tumor growth and metastasis in mice
- (2013) Kun Gao et al. CANCER LETTERS
- IL-18-Primed Helper NK Cells Collaborate with Dendritic Cells to Promote Recruitment of Effector CD8+ T Cells to the Tumor Microenvironment
- (2013) J. L. Wong et al. CANCER RESEARCH
- The Interleukin-1 Family: Back to the Future
- (2013) Cecilia Garlanda et al. IMMUNITY
- Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells
- (2013) Ivan P. Jovanovic et al. INTERNATIONAL JOURNAL OF CANCER
- The Alarmin Interleukin-33 Drives Protective Antiviral CD8+ T Cell Responses
- (2012) W. V. Bonilla et al. SCIENCE
- Serum Interleukin-33 Levels in Patients with Gastric Cancer
- (2011) Pinghu Sun et al. DIGESTIVE DISEASES AND SCIENCES
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Gene expression profiling identifies sST2 as an effector of ErbB2-driven breast carcinoma cell motility, associated with metastasis
- (2011) J Gillibert-Duplantier et al. ONCOGENE
- The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-γ production
- (2009) Elvire Bourgeois et al. EUROPEAN JOURNAL OF IMMUNOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started